Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
On Friday, Johnson & Johnson (NYSE:JNJ) announced that it would implement significant changes to offering 340B pricing for its popular drugs, Stelara and Xarelto.
周五，强生（纽交所：JNJ）宣布将对其知名药品Stelara和Xarelto的价格进行重大调整，达到3400亿美元。
Stelara (ustekinumab) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Stelara（乌斯特齐单抗）适用于中度至重度的银屑病、活动性银屑病性关节炎、克罗恩病和溃疡性结肠炎。
Xarelto (rivaroxaban) is a blood thinner that treats and helps prevent blood clots related to certain conditions involving the heart and blood vessels.
Xarelto（利伐沙班）是一种用于治疗和预防与心脏和血管相关的某些病症有关的血栓的抗凝药。
Also Read: Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies.
另请参阅：强生的银屑病药物Stelara的医保费用在药店获取时翻倍。
Beginning October 15, disproportionate share hospitals (DSHs) participating in the 340B Drug Pricing Program must buy these drugs at full price and submit data to Johnson & Johnson.
从10月15日开始，参与3400亿药品定价计划的不成比例分担医院（DSHs）必须以全价购买这些药物，并将数据提交给强生。
Once the drug's 340B status is verified, the hospitals will receive a rebate reflecting the 340B discount.
一旦确认药物的3400亿地位，医院将获得反映3400亿折扣的回扣。
The pharma giant said the policy shall take effect in approximately two months, on October 15, and the company will provide an additional grace period for rebate claims submission.
这家制药巨头表示，该政策将于约两个月后的10月15日生效，公司将为回扣申请提交提供额外的宽限期。
DSH Covered Entities will have over six months to adjust to the new policy.
参与覆盖实体将有超过六个月的时间来适应这项新政策。
In a statement, AHA said that it has informed Johnson & Johnson that its rebate model is inconsistent with the 340B statute and that the Secretary of the Department of Health and Human Services has not approved this model.
美国医院协会在一份声明中表示，已告知强生公司，其返利模式与3400亿法规不一致，卫生和公众服务部部长尚未批准该模式。
HRSA further informed the AHA that it would take appropriate action as warranted.
卫生资源与服务管理局进一步告知美国医院协会将采取必要的行动。
The drugmaker outlined that under the program, covered entities must submit rebate claims data within 45 days of dispensing the drug. However, a grace period allows for claims submissions outside the 45-day window through March 10, 2025.
药企概述称，在该计划下，覆盖实体必须在药品分配后45天内提交返利索赔数据。然而，宽限期允许在2025年3月10日之前提交超出45天时限的索赔。
"We believe this update will significantly improve program integrity while at the same time enabling covered entities to obtain the 340B price on eligible 340B sales," Johnson & Johnson said in its notice.
强生公司在通知中表示：“我们相信这一更新将显著提高计划的完整性，同时使覆盖实体能够获得符合条件的3400亿销售价格。”
Johnson & Johnson's Imbruvica is among the drugs to be a part of the first round of drug price negotiation.
强生公司的Imbruvica是首轮药品价格谈判的一部分。
Price Action: JNJ stock is up 0.49% at $164.93 at last check Monday.
股价走势：截至周一最后检查时，强生股价上涨0.49%，报164.93美元。
- Salesforce Q2 Preview: Analyst Sees Soft Cloud Demand But Highlights Data Cloud's Growing Impact.
- 赛富时Q2预览：分析师认为云需求疲软，但强调数据云的持续影响增加。
Photo via Shutterstock
图片来自shutterstock。